Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Access Pharmaceuticals Inc. Stories

2010-10-11 07:00:00

DALLAS and NEW YORK, Oct. 11 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy. Some of the findings reported in the ESMO presentation included: MuGard provided a significant improvement and/or...

2010-09-29 07:30:00

DALLAS and NEW YORK, Sept. 29 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies. As a result of the continued advancements made with its Cobalamin program, Access rebranded...

2010-09-21 07:30:00

DALLAS and NEW YORK, Sept. 21 /PRNewswire/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories....

2010-09-15 07:30:00

DALLAS and NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information. "We are proud to have launched our product website...

2010-09-14 07:30:00

DALLAS, and NEW YORK, Sept. 14 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received its first commercial order for MuGard from BioScrip (Nasdaq: BIOS), its specialty distribution partner. BioScrip's initial purchase order of MuGard, totaling over $700,000, will provide adequate inventory for its various distribution channels to support the Company's...

2010-09-08 07:30:00

DALLAS and NEW YORK, Sept. 8 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer, supportive care, today announced that the Company will present at the Rodman & Renshaw Annual Healthcare Conference in New York City on Tuesday, September 14th at 9:35AM ET in the Fahnestock Salon, located on the 5th floor of the New York Palace Hotel. On Tuesday, Jeffrey Davis, Chief Executive Officer of Access...

2010-08-24 07:30:00

DALLAS and NEW YORK, Aug. 24 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at...

2010-08-03 07:31:00

DALLAS and NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase...

2010-07-29 07:30:00

DALLAS and NEW YORK, July 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, today announced that it will host a conference call at 11:00 a.m. EDT on August 3rd, to provide an update on the Company's strategy and activities surrounding the official launch its lead product, MuGard in North America. Interested parties may participate by dialing 877-407-4019 (US) or...

2010-07-28 07:30:00

DALLAS and NEW YORK, July 28 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research has issued a research update summarizing some of the recent positive developments that the Company has been able to achieve which have led to reiteration of the 'Outperform' rating on ACCP and a six-twelve month price target of $8.00. The report can...